Mangubat, Angelito Carlo R.

HRN: 22-61-45  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/18/2023
CO-AMOXICLAV 625MG (TAB)
02/18/2023
02/25/2023
PO
625mg
Q8H
Fracture, Close, Complete, Tibia, R
Waiting Final Action 

Indication:  Empirical De-escalation    Type of Infection:  Bone & JointSkin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: